


FIGURE 3: Non-Occupational HIV Exposure: Post-Exposure Prophylaxis and Exposure Management When Reported Within 72 Hours
 Note: Regimens listed below are for individuals who weigh ≥ 40 kg; see Table 4 for PEP regimens for individuals who weigh < 40 kg.



Abbreviations: Ag/Ab, antigen/antibody; CrCl, creatinine clearance; CT/GC NAAT, chlamydia/gonorrhea nucleic acid amplification testing; HBV, hepatitis B virus; HCV, hepatitis C virus; PEP, post-exposure prophylaxis; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
Drug name abbreviations (brand name): DTG, dolutegravir (Tivicay); RAL, raltegravir (Isentress); TDF/3TC, tenofovir disoproxil fumarate/lamivudine (Cimduo); TDF/FTC, tenofovir disoproxil fumarate/emtricitabine (Truvada).
Notes: a. Do not use fixed-dose combination tablet if dose adjustment for renal failure is required. Adjust dose of TDF/FTC or TDF/3TC for patients with CrCl < 50 mL/min. See *Recommended Dose Adjustments for Use of Selected Fixed-Dose Combination ARVs in Patients with Hepatic or Renal Impairment*.
 b. For HBV and HCV post-exposure management, see guideline sections *Management of Potential Exposure to HBV* and *Management of Potential Exposure to HCV*.